Paper Details

  1. Home
  2. Paper Details

Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.

Author: BuistA S, DurcanM J, GonzalesD, HaysJ T, HurtR D, JohnstonJ A, NiauraR, RigottiN A, SachsD P, WhiteJ D, WolterT D

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Sustained-release bupropion for 12 months significantly delayed smoking relapse in people who stopped smoking with 7 weeks of bupropion treatment (55.1% vs. 42.3%). It also resulted in less weight gain (3.8 kg vs. 5.6 kg).
Paper Details　
Original Abstract of the Article :
BACKGROUND: Smoking relapse is common after successful pharmacologic treatment for smoking cessation. No previous studies have examined long-term drug therapy used expressly for prevention of smoking relapse. OBJECTIVE: To evaluate the efficacy of bupropion to prevent smoking relapse. DESIGN: Rand...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.7326/0003-4819-135-6-200109180-00011

データ提供：米国国立医学図書館（NLM）

Sustaining the Journey: Long-Term Bupropion for Smoking Cessation

The journey to quitting smoking can be a treacherous one, with many facing the temptation to relapse. This study explores the effectiveness of sustained-release bupropion, a medication often used to aid in smoking cessation, as a tool for long-term relapse prevention. The researchers conducted a randomized, controlled trial involving 784 volunteers motivated to quit smoking. Participants received open-label bupropion for seven weeks, and those who achieved abstinence were randomly assigned to receive bupropion or a placebo for 45 weeks, followed by an additional year of observation. The results demonstrated that bupropion significantly delayed smoking relapse and resulted in less weight gain compared to placebo.

The Oasis of Bupropion: Reducing Relapse and Weight Gain

The study found that bupropion had a significant impact on smoking relapse. Participants receiving bupropion were more likely to remain abstinent than those receiving placebo, with a notably longer median time to relapse. The medication also helped to mitigate weight gain, a common concern among those quitting smoking. The results suggest that bupropion plays a vital role in supporting long-term abstinence and reducing the associated risks of relapse and weight gain.

Embracing the Journey: Seeking Support and Tools

The findings from this study offer hope for those struggling to maintain their smoking cessation journey. It underscores the potential benefits of sustained-release bupropion in preventing relapse. However, it's important to remember that quitting smoking is a complex process that requires individual support and a personalized approach. Consulting with a healthcare professional and exploring available resources is crucial for navigating this path successfully.

Dr.Camel's Conclusion

This research reminds us that quitting smoking is a marathon, not a sprint. Bupropion offers a valuable tool for those embarking on this journey, helping to sustain their progress and navigate the challenging landscape of relapse.

Date :
  1. Date Completed 2001-10-04
  2. Date Revised 2019-06-19
Further Info :

Pubmed ID

11560455

DOI: Digital Object Identifier

10.7326/0003-4819-135-6-200109180-00011

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.